Dalbavancin administration
Phase 3Small molecule
Dalbavancin administration is one of 14 small molecule programs targeting Endocarditis. It is currently in Phase 3.
1
Indications
2
Total Trials
2
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
40 competitors in Endocarditis
#DrugCompanyPhaseTrials
1Zyvox
PfizerApproved
Cubicin
BBaxter Healthcare Corporation
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Gantanol
CConrado Roberto Hoffmann Filho
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Approved
Rifadin
SanofiPhase 3
Ceclor
Eli LillyApproved
Pathocil
WWyeth-Lederle Vaccines
Approved
Levaquin
WWim Janssens
Phase 3
Rifampicin
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dalbavancin administration. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details